Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 19331127)

1.

Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.

Guan M, Zhu L, Somlo G, Hughes A, Zhou B, Yen Y.

Anticancer Res. 2009 Jan;29(1):1-9.

2.

Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.

Zheng W, Guan M, Zhu L, Cai Z, Chung V, Huang H, Yen Y.

Anticancer Res. 2010 Jun;30(6):1921-30.

PMID:
20651335
3.

Constitutively active FGFR3 with Lys650Glu mutation enhances bortezomib sensitivity in plasma cell malignancy.

Otsuka M, Mizuki M, Fujita J, Kang S, Kanakura Y.

Anticancer Res. 2011 Jan;31(1):113-22.

PMID:
21273588
4.

Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.

Que W, Chen J, Chuang M, Jiang D.

APMIS. 2012 Mar;120(3):195-203. doi: 10.1111/j.1600-0463.2011.02836.x. Epub 2011 Nov 11.

PMID:
22339676
5.

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.

Ronchetti D, Greco A, Compasso S, Colombo G, Dell'Era P, Otsuki T, Lombardi L, Neri A.

Oncogene. 2001 Jun 14;20(27):3553-62.

6.

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.

Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ.

Clin Cancer Res. 2007 Nov 1;13(21):6469-78.

7.

Effect of noncompetitive proteasome inhibition on bortezomib resistance.

Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2010 Jul 21;102(14):1069-82. doi: 10.1093/jnci/djq198. Epub 2010 May 26.

8.

Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.

Lee JC, Ahn KS, Jeong SJ, Jung JH, Kwon TR, Rhee YH, Kim SH, Kim SY, Yoon HJ, Zhu S, Chen CY, Kim SH.

J Cell Biochem. 2011 Jun;112(6):1552-62. doi: 10.1002/jcb.23077.

PMID:
21344490
9.

Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.

Bisping G, Wenning D, Kropff M, Gustavus D, Müller-Tidow C, Stelljes M, Munzert G, Hilberg F, Roth GJ, Stefanic M, Volpert S, Mesters RM, Berdel WE, Kienast J.

Clin Cancer Res. 2009 Jan 15;15(2):520-31. doi: 10.1158/1078-0432.CCR-08-1612.

10.

Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.

Perez LE, Parquet N, Meads M, Anasetti C, Dalton W.

Eur J Haematol. 2010 Mar;84(3):212-22. doi: 10.1111/j.1600-0609.2009.01381.x. Epub 2009 Nov 17.

PMID:
19922463
11.

Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.

Cancer Res. 2007 Jun 1;67(11):5418-24.

12.

Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.

Meyer AN, McAndrew CW, Donoghue DJ.

Cancer Res. 2008 Sep 15;68(18):7362-70. doi: 10.1158/0008-5472.CAN-08-0575.

14.

Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.

Kim HJ, Kim SM, Park KR, Jang HJ, Na YS, Ahn KS, Kim SH, Ahn KS.

Cancer Lett. 2011 Feb 1;301(1):29-37. doi: 10.1016/j.canlet.2010.11.002. Epub 2010 Nov 30.

PMID:
21122982
16.

Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.

Kim SH, Ahn KS, Jeong SJ, Kwon TR, Jung JH, Yun SM, Han I, Lee SG, Kim DK, Kang M, Chen CY, Lee JW, Kim SH.

Eur J Pharmacol. 2011 Mar 1;654(1):10-6. doi: 10.1016/j.ejphar.2010.11.032. Epub 2010 Dec 21.

PMID:
21172343
17.

CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.

Xin X, Abrams TJ, Hollenbach PW, Rendahl KG, Tang Y, Oei YA, Embry MG, Swinarski DE, Garrett EN, Pryer NK, Trudel S, Jallal B, Mendel DB, Heise CC.

Clin Cancer Res. 2006 Aug 15;12(16):4908-15.

18.

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.

Paterson JL, Li Z, Wen XY, Masih-Khan E, Chang H, Pollett JB, Trudel S, Stewart AK.

Br J Haematol. 2004 Mar;124(5):595-603.

PMID:
14871245
19.

Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.

Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, Ueda M, Nobuyoshi M, Oh I, Sato K, Suzuki T, Ozaki K, Mori M, Nagai T, Muroi K, Kano Y, Furukawa Y, Ozawa K.

Oncogene. 2009 Jan 15;28(2):231-42. doi: 10.1038/onc.2008.385. Epub 2008 Oct 13.

PMID:
18850009
20.

The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib.

Walsby EJ, Pratt G, Hewamana S, Crooks PA, Burnett AK, Fegan C, Pepper C.

Mol Cancer Ther. 2010 Jun;9(6):1574-82. doi: 10.1158/1535-7163.MCT-10-0104. Epub 2010 Jun 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk